Publications

5674 Results

SWOG S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX), capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC)

Authors
CG Leichman;S McDonough;S Smalley;K Billingsley;H Lenz;A Hezel;M Velasco;M Beldner;K Guthrie;C Blanke;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl;abstr 3516); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S0713

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NRG/Alliance S1207 (NCT01674140)

Authors
M Chavez-Macgregor;W Barlow;L Pusztai;MP Goetz;P Rastogi;P Ganz;EP Mamouns;S Paik;H Bandos;J Gralow;D Lew;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS637); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Breast
Study Number(s)
S1207

SWOG 1107: Parallel randomized phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (pts) with advanced papillary renal cell carcinoma (pRCC)

Authors
P Twardowski;M Plets;ER Plimack;N Aggarwal;C Tangen;N Vogelzang;IM Thompson;PN Lara
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4523); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Genitourinary
Study Number(s)
S1107

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307(NCT00127205)

Authors
J Gralow;W Barlow;A Paterson;D Lew;A Stopeck;D Hayes;D Hershman;M Schubert;M Clemons;C Van Poznak;EC Dees;JN Ingle;C Falkson;A Elias;M Messino;J Margolis;S Dakhil;H Chew;R Livingston;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 33:5s, 2015 (suppl; abstr 503);American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
Year
2015
Research Committee(s)
Breast
Study Number(s)
S0307

Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)

Authors
M Dickler;WT Barry;CT Cirrincione;M Ellis;M Moynahan;H Rugo;B Schneider;D Tripathy;C Hudis;E Winer
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 501); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Breast
Study Number(s)
CTSU/C40503

SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Authors
R Kim;S McDonough;A El-Khoueiry;T Bekaii-Saab;K Guthrie;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS4142); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), TIPS, poster session;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S1310

Intergroup pilot study of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by capecitabine-based chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101

Authors
MHG Katz;Q Shi;SA Ahmad;J Herman;R Marsh;E Collisson;L Schwartz;H Kindler;AM Lowy;AP Venook
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4008); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021101

SWOG S0809: A phase II intergroup trial of adjuvant capecitabine/gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma

Authors
E Ben-Josef;K Guthrie;A El-Khoueiry;C Corless;M Zalupski;A Lowy;CR Thomas;SR Alberts;L Dawson;K Micetich;M Thomas;A Siegel;C Blanke
Journal / Conference
Journal of Clinical Oncology Aug 20;33(24):2617-2622
Year
2015
Research Committee(s)
Gastrointestinal
PMID
PMID25964250
PMC
PMC4534524
Study Number(s)
S0809

Safety and tolerability of the combination of ATRA + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): initial report of the SWOG/Alliance/ECOG S0535 trial (NCT00551460)

Authors
J Lancet;M Othus;R Komrokji;S Coutre;D DeAngelo;M Tallman;M Litzow;F Appelbaum
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 7016); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Leukemia
Study Number(s)
S0535

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT00658814)

Authors
S Nand;N Achille;M Othus;K Phelan;S Zhang;K Cooper;J Godwin;F Appelbaum;J Radich;H Erba;N Zeleznik-Le
Journal / Conference
Journal of Clinical Oncology J Clin Oncol 33:5s (suppl; abstr 7060); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster;
Year
2015
Research Committee(s)
Leukemia
Study Number(s)
S0703